Verisante Technology Inc. | Income Statement

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
Sales/Revenue
775.30
218.80
139.00
26.40
Cost of Goods Sold (COGS) incl. D&A
1,564.30
1,196.70
1,165.00
925.10
Gross Income
789.00
977.90
1,026.00
898.70
SG&A Expense
4,120.10
2,367.90
1,385.10
618.70
EBIT
4,909.10
3,345.80
2,435.60
1,551.90
Unusual Expense
-
18.80
85.40
93.00
Non Operating Income/Expense
0.70
131.20
24.50
3.30
Interest Expense
-
-
14.90
-
Pretax Income
4,896.10
3,233.40
2,389.60
1,641.60
Consolidated Net Income
4,896.10
3,233.40
2,389.60
1,641.60
Net Income
4,896.10
3,233.40
2,389.60
1,641.60
Net Income After Extraordinaries
4,896.10
3,233.40
2,389.60
1,641.60
Net Income Available to Common
4,896.10
3,233.40
2,389.60
1,641.60
EPS (Basic)
0.07
0.04
0.03
0.02
Basic Shares Outstanding
72,452.80
81,748.70
90,647.10
94,322.60
EPS (Diluted)
0.07
0.04
0.03
0.02
Diluted Shares Outstanding
72,452.80
81,748.70
90,647.10
94,322.60
EBITDA
3,849.60
2,216.10
1,337.60
627.50
Other Operating Expense
-
-
24.60
34.60
Non-Operating Interest Income
12.30
-
-
-

About Verisante Technology

View Profile
Address
2639 Viking Way
Richmond British Columbia V6V 3B7
Canada
Employees -
Website http://www.verisante.com
Updated 07/08/2019
Verisante Technology, Inc. a medical device company, which is engaged in development, regulatory, production and commercialization of skin cancer detection systems. Its products include Verisante Aura and Verisante Core. The Verisante Aura is a multimodality imaging and spectroscopy system designed to aid in the early detection of skin cancer.